
LeonaBio Inc (LONA) Stock Forecast & Price Target
LeonaBio Inc (LONA) Analyst Ratings
Bulls say
LeonaBio is a clinical-stage biopharmaceutical company that operates as a single operating segment, developing and commercializing novel therapeutics, including lasofoxifene and ATH-1105, with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). Its top-tier drug candidates have demonstrated strong clinical data, with results showing statistically significant improvement in PFS and potential to become one of the next endocrine therapy backbones in the large ER+/HER2- mBC market. The company is well-positioned to compete in this market with its pipeline of small-molecule drugs targeting the HGF/MET pathway. With additional future shots at goal in other mutational subsets and a strong financial position, LeonaBio has minimal risk and a high potential for growth in the oncology space.
Bears say
LeonaBio is a clinical-stage biopharmaceutical company operating in a highly competitive market. While their key drug candidates have shown promising results in clinical trials, the company's current financials and resources may not be enough to effectively commercialize and compete against established players. Additionally, the company's dependence on a few drug candidates and lack of diversification in their pipeline pose significant risks to its long-term success.
This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.
LeonaBio Inc (LONA) Analyst Forecast & Price Prediction
Start investing in LeonaBio Inc (LONA)
Order type
Buy in
Order amount
Est. shares
0 shares